<DOC>
	<DOCNO>NCT01970540</DOCNO>
	<brief_summary>Phase I Multicenter , Open-label , Clinical Pharmacokinetic Study PM01183 Combination Fixed Doxorubicin Non- Heavily Pretreated Patients Selected Advanced Solid Tumors determine maximum tolerate dose ( MTD ) recommend dose ( RD ) PM01183 combination doxorubicin , characterize safety profile feasibility combination , characterize pharmacokinetics ( PK ) combination , obtain preliminary information clinical antitumor activity , explore feasibility , safety efficacy potential improvable dose combination select tumor type [ i.e . small cell lung cancer ( SCLC ) endometrial cáncer ] evaluate pharmacogenomics ( PGx ) tumor sample patient expose PM01183 doxorubicin RD order ass potential marker response and/or resistance .</brief_summary>
	<brief_title>Study Escalating Doses PM01183 Combination With Fixed Doxorubicin Patients With Specific Advanced Unresectable Solid Tumors</brief_title>
	<detailed_description>The study currently meet primary end point recruit patient treat RD expansion cohort select tumor type , specifically : endometrial adenocarcinoma , neuroendocrine tumor , small-cell lung cancer ( SCLC ) .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Uterine Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Voluntarily write informed consent Age : 18 75 year ( inclusive ) . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) ≤ 1 . Cohort patient SCLC endometrial cáncer ECOG PS ≤ 2 . Life expectancy ≥ 3 month . Patients histologically/cytologically confirm diagnosis advance disease follow tumor : 1 . Breast cancer 2 . Softtissue sarcoma 3 . Primary bone sarcoma . 4 . Gynecologic tumor ( endometrial adenocarcinoma , epithelial ovarian cancer ... ) 5 . Hepatocellular carcinoma 6 . Gastroenteropancreatic neuroendocrine tumor 7 . Small cell lung cancer ( SCLC ) 8 . Gastric cancer 9 . Bladder cancer 10 . Adenocarcinoma unknown primary site At least three week since last anticancer therapy , include radiotherapy Adequate bone marrow , renal , hepatic , metabolic function Left ventricular ejection fraction ( LVEF ) echocardiogram ( ECHO ) multiplegated acquisition ( MUGA ) scan within normal range ( accord institutional standard ) . Women childbearing potential must negative serum pregnancy test study entry . Both woman men must agree use medically acceptable method contraception throughout treatment period six week discontinuation treatment Concomitant diseases/conditions : History presence unstable angina , myocardial infarction , congestive heart failure , clinically significant valvular heart disease within last year . Symptomatic uncontrolled arrhythmia Ongoing chronic alcohol consumption , cirrhosis Active uncontrolled infection . Known human immunodeficiency virus ( HIV ) infection . Any major illness , Investigator 's judgment Brain metastases leptomeningeal disease involvement . Men woman childbearing potential use effective method contraception Patients radiation therapy 35 % bone marrow . This criterion apply cohort patient SCLC endometrial cáncer . History previous bone marrow and/or stem cell transplantation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>lurbinectedin</keyword>
	<keyword>PM01183</keyword>
	<keyword>tumor</keyword>
	<keyword>cancer</keyword>
	<keyword>Pharma Mar</keyword>
</DOC>